Guzip Biomarkers Corporation
Update：2026/03/31
Industries
Main Industry
Biotechnology
Main Product/Service
Guzip’s flagship products include MPap® and RitaPap®, both of which use methylation-specific qPCR to detect methylation status of key genes; MPap uses cervical scrape samples, while RitaPap uses tampon-collected samples.
They also develop a MUrine test (
They also develop a MUrine test (
Founded Year
2018
Unified Business No.
50859246
Status
Active
Number of Employees
10
Total Paid-in
Capital
38,723,910 (NT$)
Location of Company
Taiwan
, Hsinchu County
Exit Status
Acquired(2025)
Year of establishment, company status, responsible person, paid-in capital amount, and registered address are sourced from the "Commerce Industrial Services Portal, Department of Commerce, MOE. Exit status refers to various situations, including emerging stock exchanges (e.g., potential exits), mergers and acquisitions (M&A), and IPOs. The overseas development countries are collected through information provided by startups themselves and the information filled in when registering for matchmaking events. Therefore, the information cannot be updated in real time. If you wish to make corrections, please email findit.tier@gmail.com. Thank you.
Notice: This data is compiled from public sources for reference only. We have no direct affiliation with the company and are not their contact person. Please do not contact this platform for company inquiries.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
Guzip Biomarkers Corporation, founded in 2018 as a spin‑out from Taipei Medical University, is a research‑driven biotech company specializing in epigenetics and DNA methylation.
Their mission is to develop novel methylation‑based biomarkers for clinical applications, particularly in women’s health.
Their mission is to develop novel methylation‑based biomarkers for clinical applications, particularly in women’s health.
Corporate Video
